TABLE 3.
Subgroup analysis.
| Outcome | Subgroup factor | Number of study | Cases (EG/CG) | I 2 (%) | Heterogeneity (P) | Pooling model | Z test (P) |
|---|---|---|---|---|---|---|---|
| ALP | — | ||||||
| OP type | — | — | — | — | — | — | |
| Senile OP | 6 | 274/274 | 86.9 | <0.0001 | Random | <0.0001 | |
| Primary OP | 5 | 241/252 | 94.2 | <0.0001 | Random | 0.001 | |
| Postmenopausal OP | 1 | 63/63 | — | — | Fixed | <0.0001 | |
| Control medication | — | — | — | — | — | — | |
| ALE alone | 3 | 145/145 | 0 | 0.710 | Fixed | <0.0001 | |
| ALE combined with OP basic treatment | 9 | 433/444 | 95.3 | <0.0001 | Random | <0.0001 | |
| VAS | — | — | — | — | — | — | — |
| OP type | — | — | — | — | — | — | |
| Senile OP | 2 | 110/108 | 0 | 0.742 | Fixed | <0.0001 | |
| Primary OP | 1 | 45/45 | — | — | Fixed | <0.0001 | |
| Postmenopausal OP | 3 | 147/147 | 87.4 | <0.0001 | Random | 0.003 | |
| Control medication | — | — | — | — | — | — | |
| ALE alone | 3 | 140/140 | 98.1 | <0.0001 | Random | 0.029 | |
| ALE combined with OP basic treatment | 3 | 162/160 | 94.8 | <0.0001 | Random | 0.002 |
OP, osteoporosis; ALE, alendronate; EG, experimental group; CG, control group; ALP, alkaline phosphatase; VAS, Visual Analog Score.